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Simple Summary: Alternatives to antibiotic therapy for mastitis in dairy cattle are of interest to
the dairy industry and society. Reduced use of antibiotics while maintaining or improving animal
welfare is desirable. We studied the intramammary infusion of casein hydrolysate, alone or combined
with standard dry cow treatment, at the beginning of the dry period before cows have their next calf.
The effects on mammary involution and milk quality suggested that infusion of casein hydrolysate
alone or combined with internal teat sealant may be an alternative to antibiotic dry cow therapy.
Abstract: Alternatives to routine antibiotic treatment of dairy cattle during the dry period before
their next calving are of interest. This was a preliminary study of whether intramammary infusion of
casein hydrolysate, administered alone or combined with standard dry treatment, accelerated the rate
of mammary involution early in the dry period. Four treatments were studied in a split udder design.
One udder half was assigned a treatment, and the contralateral half was administered dry cow
treatment + internal teat sealant as a control. Treatments were casein hydrolysate, casein hydrolysate
+ dry cow treatment, casein hydrolysate + teat sealant and casein hydrolysate + dry cow treatment
+ teat sealant. Cows (n = 16) were blocked by a number of intramammary infections per udder
half (0 or 1+) and randomized to treatments. Milk production was not different between control or
treated udder halves post-calving. A generalized linear mixed model tested for differences between
the treatment groups in the concentration of mammary involution indicators in milk: somatic cell
count, bovine lactoferrin and bovine serum albumin. At 7 days, dry udder halves treated with casein
hydrolysate had higher milk concentrations of lactoferrin than those treated with casein hydrolysate
+ dry cow treatment, casein hydrolysate + teat sealant and control. At 10 days dry, bovine serum
albumin was higher in udder halves treated with casein hydrolysate than in those treated with casein
hydrolysate + dry cow treatment, casein hydrolysate + dry cow treatment + teat sealant and control.
Post-calving, casein hydrolysate-treated udder halves produced 51% of total milk, unchanged from
before dry-off. There were seven total intramammary infections entering the dry period, all caused
by coagulase-negative staphylococci. Cure rates (3/7, 43%) were not different among all treatments
and control, partly because of the small sample size. Intramammary infusion of casein hydrolysate at
the end of lactation may be an alternative or possible adjunct to antibiotic dry cow therapy.
Keywords: dry cow therapy; casein hydrolysate; involution; intramammary infection; masti-
tis; bovine
1. Introduction
The importance of the dry period in dairy cows has long been established within
the dairy industry [1,2]. Cows may carry existing intramammary infections (IMI) into
the dry period that remain present into the next lactation and are at an increased risk for
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acquiring new IMI immediately following cessation of milking [3,4]. Persistent and new IMI
following calving have been associated with increased SCC and decreased milk production
in the subsequent lactation [5]. Currently, the standard practice for mitigating IMI risk
at dry-off is the blanket use of intramammary dry cow antibiotic therapy (DCT) [6,7].
Previous studies have demonstrated that blanket use of DCT (BDCT) has been effective
in eliminating many existing IMI present at dry-off and preventing new IMI in the early
dry period [8,9]. Additionally, the routine use of DCT has been shown to effectively lower
bulk tank milk SCC [10] and nearly eradicate certain pathogens in some countries [11].
Recently, the practice of BDCT has come under international scrutiny because of concerns
for antibiotic overuse [12].
Among consumers, scientists and health professionals, there is increasing concern over
the widespread use of antibiotics in food-producing animals and the potential contribution
to antimicrobial resistance, both in veterinary pathogens and in human medicine [13]. The
data remain indeterminate on whether antibiotic use in livestock definitively causes antimi-
crobial resistance in humans; however, associations have been found between practices that
restrict on-farm antimicrobial usage and a decrease in the prevalence of antibiotic-resistant
bacteria [14]. Within the dairy industry, reducing or eliminating BDCT has become a major
focus as a potential change to reduce antibiotic use. Scientific and industry interest has
emerged for developing strategies for selective use of dry cow therapy (SDCT) as a possible
method of reducing antimicrobial use while still maintaining the benefits of reducing the
incidence rate of clinical mastitis and lowering bulk tank SCC [15,16]. Studies investigating
the efficacy of SDCT have produced conflicting results [15,16]. Cows dried off without
antibiotics experience higher rates of both clinical and subclinical mastitis in the following
lactation, and any economic benefit gained from reducing antimicrobial use at dry-off is
lost by the increase in mastitis cases [12]. There are disadvantages to both BDCT and SDCT,
and a need for an alternative dry cow treatment exists within the dairy industry.
When drying off single mastitic quarters mid-lactation, casein hydrolysate intramam-
mary infusion was associated with successful cessation of lactation in treated quarters
with no signs of cow discomfort [17,18], decreased cow-level SCC during the remainder
of lactation and return to milk production with decreased SCC in all previously mastitic
quarters following calving [18]. Cows dried off and treated with casein hydrolysate as the
only dry cow treatment exhibited more cow comfort and less mammary gland distension
compared with cows dried off abruptly with no treatment [19]. When used in combina-
tion with antibiotic dry cow treatment, casein hydrolysate was associated with increased
bacteriological cures and higher milk yield compared with antibiotic dry treatment alone;
those authors also stated that casein hydrolysate should be studied in combination with
internal teat sealants and to evaluate whether it might result in faster mammary gland
involution [20]. We investigated whether intramammary infusion of casein hydrolysate
would be associated with faster mammary involution in comparison to that following
other dry treatments during the first 10 days of the dry period, when most of mammary
involution takes place [21].
This study evaluated the effects of casein hydrolysate alone or in combination with
antibiotic dry cow treatment and/or an internal teat sealant as well as a standard dry cow
treatment control. The antibiotic dry cow treatment and internal teat sealant were chosen
because of their widespread use in the dairy industry [22].
2. Materials and Methods
2.1. Study Animals and Permits
Study cows were housed on 6 commercial Utah dairy farms. All farms followed a
twice daily milking schedule, and cows were housed on shaded dry lots that are typical
of the region. Post-calving management was similar on all farms including removal of
the calf from the dam soon after calving. Lactation number, days in milk (DIM) and
estimated calving date were obtained from dairy records. To be eligible for the study,
cows were pregnant and scheduled for dry-off within 40 to 70 days before expected
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parturition. Cows with nonlactating quarters or presenting with clinical mastitis were
excluded. All animal handling and treatments in this study were performed in compliance
with a Utah State University Institutional Animal Care and Use Committee (IACUC)
approved protocol #2739.
Casein hydrolysate is not labeled for use in food animals in the U.S.; this study
was conducted under conditional U.S. Food and Drug Administration (FDA) permission
and followed typical guidelines for milk and meat withhold (60 d) times for commercial
treatments and FDA-suggested milk withhold time (72 h) for casein hydrolysate.
2.2. Experimental Design
A completely randomized block design was used. All cows were blocked into two
groups by number of quarters containing a subclinical IMI (either 0 or 1+). Infection status
was based on culture results from a milk sample collected 4 days prior to dry-off. All
aseptic milk samples for culture during the study were collected by study personnel. There
were 4 treatment groups and one control: casein hydrolysate; casein hydrolysate + dry cow
antibiotic (Dry-Clox, Boehringer Ingelheim, Ridgefield, CT, USA); casein hydrolysate +
teat sealant (Orbeseal, Zoetis Animal Health, Parsippany, NJ, USA); casein hydrolysate +
dry cow antibiotic + teat sealant; and dry cow treatment + teat sealant (control). One half
of each udder, front and rear quarters combined, was randomized to a treatment group,
while the other half received control, allowing every cow to serve as her own control and
minimize the effect of variability between animals [23,24]. Study cows were marked with
corresponding colored leg bands on both hind legs, along with an additional leg band
used to identify the control side. Treatments were preassigned using a random number
generator to assign which udder half would be treated versus control, followed by the
treatment group assignment. Assignment of treatment sides and groups was forced only
for the last cow within each block to ensure blocks were balanced with an equal number of
animals per treatment group and an equal distribution of treatments and controls between
right and left udder halves.
A second milk sample for culture was taken immediately prior to the time of treatment,
for later evaluation of bacteriological cure. Bacteriological cure of previous IMI and
new infection rates were not primary objectives of this study. However, involution is a
mechanism of curing existing IMI during the dry period and an important outcome for
any treatment during the dry period in dairy cattle [25,26]. Quarters which had the same
organism isolated from the same quarter from both pre-treatment samples (“+, +”) were
eligible for bacterial cure evaluation post-calving. Postpartum, the previously treated
quarters were resampled 3 times, at 3 DIM, 8–14 DIM and 15–21 DIM.
Bacterial culture of milk samples was performed according to standard methods
approved by the National Mastitis Council [27,28]. In brief, a 10 µL inoculum of milk was
streaked onto washed cow blood agar and placed in a standard, non-CO2 incubator at 37 ◦C
for 24 h. Plates were examined for bacterial growth at 24 and 48 h; organism identification
was determined primarily by colony morphology and confirmed by secondary biochemical
tests. Presence of one colony was considered positive for identification; therefore, the
detection limit was 100 colony-forming units (CFU/mL). If more than 3 different types
of bacteria were isolated, this was defined as contamination. However, any isolation of
Staphylococcus aureus was defined as a valid isolate.
2.3. Case Definitions and Inclusion Criteria
The bacteriologic case definitions were: cure = all 3 post-calving cultures negative for
any bacteria that were isolated from both pre-treatment samples; chronic (failed to cure)
= any bacteria isolated from both pre-treatment samples that were also isolated from at
least one post-calving culture; new IMI = any organism isolated from the first post-calving
culture that was not present in either pre-treatment sample. Cows whose pre-treatment
cultures resulted in no growth from one sample but growth in another (“+, −” or “−, +”)
and/or different organisms isolated from each sample were ineligible for bacterial cure
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evaluation post-calving. All cows were eligible for new infections, including with a new
pathogen if they had a different pathogen causing IMI before dry-off.
Cows meeting inclusion criteria were administered treatment at their scheduled dry-
off time. All treatments were administered by study personnel. Prior to receiving treatment,
all cows were bucket milked by udder half for their final milking, in order to obtain udder
half milk weights and determine proportional contributions to total cow milk production.
A second individual quarter milk sample was collected immediately prior to receiving
treatment. Following milking and sample collection, the front and rear quarters of each
udder half were infused aseptically with the preassigned treatment or control. Teats were
dipped with an iodine-based germicide post-treatment, and cows were immediately moved
to nonlactating housing. Individual quarter milk samples were collected again at d 2, d 4,
d 7 and d 10 post-dry-off, for a total of 6 sampling dates and 24 quarter samples per cow.
If teat sealant was part of the treatment, it was not administered until after the final milk
sample collection at d 10 post-dry-off. In order to be minimally disruptive to the involution
process, no more than 10 mL of milk was removed from each quarter per sample.
2.4. Mammary Involution Markers in Milk
Collected milk samples were analyzed for the established biomarkers of involution
direct microscopic SCC (DMSCC), bovine lactoferrin (bLf) and bovine serum albumin
(BSA) [29]. Following parturition, milk from treated cows was withheld from the bulk
tank milk for 72 h pending a negative antibiotic residue test (Delvotest-NT, Thermo Fisher,
Waltham, MA, USA). At 72 h (3 DIM) post-calving, bucket milking by udder half was
repeated, and individual quarter samples were collected for bacterial culture. Quarter
sampling for bacterial culture was repeated once between 8 and 14 DIM and again once
between 15 and 21 DIM.
Concentrations of milk BSA and bLf were measured using the lactoferrin quantitative
ELISA and bovine serum albumin quantitative ELISA kits (BioMatik, Wilmington, DE,
USA). Procedures were performed according to manufacturer’s instructions. The Form
2400 FDA method was used to determine DMSCC according to the standards of the
National Conference on Interstate Milk Shipments [30].
2.5. Casein Hydrolysate
Two batches of casein hydrolysate were prepared as previously described [18,31].
Each batch of casein hydrolysate was screened for bacterial contamination by inoculating
tryptic soy broth with 1 mL of the solution, incubating for 24 h and inoculating 100 µL
onto blood agar. Blood agar plates were incubated for a total of 48 h at 37 ◦C and read
at 24 and 48 h for bacterial growth. A separate blood agar plate was plated directly with
100 µL of non-enriched casein hydrolysate and then incubated and examined in the same
way. The definition of an uncontaminated batch was when no growth of any bacterial
colonies was observed on either direct or enriched cultures. Protein concentration for each
batch was quantified via bicinchoninic acid assay (BCA, Thomas Scientific, Swedesboro,
NJ, USA), according to manufacturer’s instructions. The BCA assay is commonly used
for protein quantification [32]. Final concentration of casein hydrolysate solutions was
5.6 mg/mL, for a total dose of 84 mg of hydrolyzed casein per 15 mL dose. Purity was
assessed using sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE,
Thermo Fisher, Waltham, MA, USA) by comparing resulting bands to known molecular
weights of hydrolyzed casein.
2.6. Milk Production Monitoring
All cows were bucket milked at their final milking before treatment and again at 72 h
post-calving, in order to measure the proportion of total cow milk production from each
udder half. This was an indication of whether any treatment was associated with increased
or decreased milk production during the next lactation compared to the contralateral udder
half. Bucket milking used clear, graduated 80 lb (36.3 kg) portable buckets. Two separate
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bucket milking units were used in order to milk each udder half. Teat cup plugs were used
to seal the opposite half of the 4-claw milking unit.
2.7. Statistical Analysis
Statistical analyses were performed using SAS Studio (Statistical Analysis System
Institute, Cary, NC, USA), using the generalized linear mixed model procedure (GLIMMIX).
Milk production by udder half was compared and analyzed by Student’s t-test. The
predictor variables time since dry-off and treatment were viewed as fixed effects, individual
cow ID was treated as a random effect and the interaction between time and treatment
was analyzed for each outcome variable. Natural log transformations were carried out
for all continuous outcome variables to correct for the wide range of numerical values
resulting in non-homogenous variances. Categorical outcomes of cure, chronic and new
IMI were compared for significant differences between treatments using Fisher’s exact test.
Differences were considered statistically significant when p ≤ 0.05 for all analyses.
3. Results
A total of 16 dairy cows, 12 Holsteins and 4 Jerseys were enrolled in this study. Cows
ranged in parity from first through seventh lactations, with an average of 3.1 lactations
and 337 DIM. There were no statistically significant differences between each treatment
group in DIM (casein hydrolysate = 359, casein hydrolysate + dry cow treatment = 352,
casein hydrolysate + teat sealant = 331, casein hydrolysate + dry cow treatment + teat
sealant = 306), average lactation number (casein hydrolysate = 3.0, casein hydrolysate +
dry cow treatment = 3.0, casein hydrolysate + teat sealant = 3.3, casein hydrolysate + dry
cow treatment + teat sealant = 3.3) or udder half percentages of total cow milk between
any of the treatment groups or the control group before treatment (all p ≥ 0.20, ANOVA).
There were also no significant differences between pre- and post-treatment contributions
of udder halves to total cow milk production within or between all treatment groups and
the control (all p ≥ 0.06, ANOVA).
All treated cows completed the dry period and calved near their estimated due date
without complication. All cows tested negative for antimicrobial residues at 72 h post-
calving (Delvotest-NT). One cow died 36 h after calving for unknown reasons—mastitis
was ruled out at necropsy—and was not replaced; therefore, 15 cows finished with complete
datasets. Post-calving milk weight and bacterial cultures were the only data points unable
to be collected from the cow that died, meaning n = 16 for all other outcomes.
The 15 cows (60 quarters) that survived long enough post-calving for evaluation of
cures and new infections had been quarter sampled twice before treatment, at 4 days prior
to treatment and again at dry-off. Twenty-seven quarters (45%) grew a bacterial organism,
but only seven quarters grew the same bacterial isolate in both pre-treatment samples and
were eligible for a bacterial cure evaluation. All seven intramammary infections before
dry-off were caused by coagulase-negative staphylococci (CNS) isolated in pure culture.
The other 20 quarters had bacterial growth in at least one of their pre-treatment samples
but were ineligible for cure rate data either because one sample produced no growth or
there were different isolates in the two samples. The most common isolates were CNS
(n = 72) and non-agalactiae streptococci (Strep spp.) (n = 28) (Table 1). No samples were
contaminated. There were no chronic failures of treatment defined only by a positive
culture result from the third and final culture samples after calving; all cultures from 15 to
21 DIM confirmed the cures or failures already detected.
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Table 1. Bacteria isolated from all milk cultures before dry-off and after calving.
Time When Sampled and Culture Results (Number of Qtrs. Positive)
Bacteria D-4 ¥ D0 £ 3 DIM ∞ 8–14 DIM 15–21 DIM New IMI γ
CNS § 12 15 17 15 13 7
Strep spp. † 5 1 6 8 8 5
Staph aureus 1 0 0 0 0 0
Pseudomonas spp. 0 4 0 1 1 0
E. coli 0 5 0 0 0 0
Prototheca sp. 0 0 1 1 1 1
Proteus spp. 0 0 0 1 0 0
Trueperella pyogenes 0 0 1 1 1 1
No Growth 48 42 38 41 41 0
Total 66 67 63 68 65 14
¥ D-4 = 4 days before dry-off and dry treatment; £ D0 = immediately before dry-off and dry treatment; ∞ DIM = days in milk; § CNS =
coagulase-negative staphylococci (includes 7 on D-4 and D0 in same quarters that defined pre-treatment intramammary infection (IMI) in
Table 2); † Strep spp. = non-agalactiae streptococci; γ New IMI = Any organism isolated from the first post-calving culture that was not
present in either pre-treatment sample. These are the 14 new IMI shown in Table 2.
Table 2. Bacteriological cures and chronic cases of intramammary infections during the dry period by treatment group.
Pre-Treatment Culture Results (Number of Qtrs. Infected) Post-Treatment Culture Results
Treatment Group IMI ¥ Mixed £ NG ∞ Cure § Chronic † New IMI γ







b 0% (0/1) c 13% (1/8)
Casein hydrolysate
+ teat sealant 2 1 3





0 1 7 N/A N/A c 13% (1/8)
Control 2 12 16 a 50% (1/2) b 50% (1/2)
c 27% (8/30)
1
Total 7 20 33 43% (3/7) 57% (4/7) 23% (14/60)
¥ IMI = Intramammary infection; same mastitis organism isolated from both pre-treatment samples; IMI are eligible to be either cure or
chronic following dry cow treatment and subsequent calving. All 7 IMI were caused by coagulase-negative staphylococci isolated in pure
culture. £ Mixed = different mastitis organisms isolated from pre-treatment cultures (all isolates shown in Table 1); ∞ NG = no growth
in either pre-treatment sample; § Cure = all 3 post-treatment cultures negative for pre-treatment IMI organism; † Chronic = at least 1
post-treatment culture positive for pre-treatment IMI organism; γ New IMI = any organism isolated from the first post-calving culture that
was not present in either pre-treatment sample (all isolates shown in Table 1); 1 One cow died before post-treatment cultures could be taken;
values within a column with the same superscript are not significantly different (p > 0.05).
Bacterial cures during the dry period for the seven CNS cases present at dry-off were
as follows: casein hydrolysate = 0/2, casein hydrolysate + dry cow treatment = 1/1, casein
hydrolysate + teat sealant = 1/2, casein hydrolysate + dry cow treatment + teat sealant =
N/A, control = 1/2. Therefore, the overall cure rate was 2/5 (40%) across all treatments
and 1/2 (50%) for control (Table 2). Chronic (failed cure) cases were as follows: casein
hydrolysate = 2/2, casein hydrolysate + dry cow treatment = 0/1, casein hydrolysate +
teat sealant = 1/2, control = 1/2. New infections detected after calving were as follows:
casein hydrolysate = 3/8 (two CNS, one Trueperella pyogenes); casein hydrolysate + dry
cow treatment = 1/8 (Strep spp.); casein hydrolysate + teat sealant = 1/6 (CNS); casein
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hydrolysate + dry cow treatment + teat sealant 1/8 (Strep spp.); and control = 8/30 (four
CNS, three Strep spp., one Prototheca spp.). Therefore, overall new infection rates were 6/30
(20%) of quarters across all treatments and 8/30 (27%) of control quarters (Table 2). The
cure rate was not significantly different between treatment groups or control (Fisher’s exact
test, all p ≥ 0.33). There were also no significant differences in new infection rates during
the dry period (Fisher’s exact test, all p ≥ 0.65).
All measured outcome variables (indicators of involution) increased significantly from
the day of drying-off (d 0) to d 10 (p < 0.0001, GLIMMIX), which is to be expected as a
natural process of involution [29,33,34] (Figures 1–3). However, no significant differences
were found in DMSCC between treatment groups (p > 0.30), nor was there a time ×
treatment effect on DMSCC (p > 0.61) (Table 3, Figure 1). Only bLf and BSA showed a
significant time × treatment interaction (p = 0.01, GLIMMIX) (Table 3, Figures 2 and 3).
Cows in the casein hydrolysate group had a higher concentration of bLf at d 7 than cows in
the casein hydrolysate + dry cow treatment and casein hydrolysate + teat sealant treatment
groups and control (all p ≤ 0.02, GLIMMIX) (Table 3, Figure 2). At d 10, cows dry treated
with casein hydrolysate had a higher concentration of BSA than casein hydrolysate + dry
cow treatment, casein hydrolysate + dry cow treatment + teat sealant and control cows (all
p ≤ 0.04, GLIMMIX) (Table 3, Figure 3).
Animals 2021, 11, x FOR PEER REVIEW 7 of 13 
Animals 2021, 11, x. https://doi.org/10.3390/xxxxx www.mdpi.com/journal/animals 
 
negative for pre-treatment IMI organism; † Chronic = at least 1 post-treatment culture positive for 
pre-treatment IMI organism; γ New IMI = any organism isolated from the first post-calving culture 
that was not present in either pre-treatment sample (all isolates shown in Table 1); 1 One cow died 
before post-treatment cultures could be taken; values within a column with the same superscript 
are not significantly different (p > 0.05). 
 s red outcome variables (indicators of involution) increased sig ificantly 
from the day of drying-off (d 0) to d 10 (p < 0.0001, GLIMMIX), w ich is to be expected as 
a natural process of involution [29, 3,34] (Figures 1–3). However, no significant differ-
ences were found in DMSCC b tween treatment grou s (p > .30), nor was there a time × 
tr t t ff t   (   . ) ( l  , i r  ). l  f     
si ifica t ti e × treatment interaction (p = 0.01, GLIMMIX) (Table 3, Figures 2 a  3). 
o s i  t e casei  y rolysate group had a higher concentration of bLf at d 7 than cows 
in the casein hydrolysate + dry cow treatment and casein hydrolysate + teat sealant treat-
ment groups and control (all p ≤ 0.02, GLIMMIX) (Table 3, Figure 2). At d 10, cows dry 
treated with casein hydrolysate had a higher concentration of BSA than casein hydrolysate 
+ dry cow treatment, casein hydrolysate + dry cow treatment + teat sealant and control 
cows (all p ≤ 0.04, GLIMMIX) (Table 3, Figure 3). 
 
Figure 1. SCC (thousands/mL) by days dry and dry treatment group; no significant differences between treatments found. 
CH= casein hydrolysate; CHDC = casein hydrolysate + dry cow treatment; CHTS = casein hydrolysate + teat sealant; 










0  D A Y S  D R Y 2  D A Y S  D R Y 4  D A Y S  D R Y 7  D A Y S  D R Y 1 0  D A Y S  D R Y
SCC in milk during the first 10 days dry (x1000)
CH CHDC CHTS CHDCTS Control
Figure 1. SCC (thousands/mL) by days dry and dry treatment group; no significant differences between treatments found.
CH= casein hydrolysate; CHDC = casein hydrolysate + dry cow treatment; CHTS = casein hydrolysate + teat sealant;
CHDCTS = casein hydrolysate + dry cow treatment + teat sealant; Control = dry cow treatment + teat sealant.
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dry (p < 0.05, GLIMMIX). CH = casein hydrolysate; CHDC = casein hydrolysate + dry cow treatment; CHTS = casein
hydrolysate + tea sealant; CHDCTS = casein hydrolysate + dry cow treatment + teat sealant; Control = dry cow treatment
+ teat sealant.
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2 days dry x a 0.28 (n = 8) a 0.56 (n = 8) a 0.74 (n = 8) a 0.55 (n = 8) a 0.54 (n = 32)
SD 0.01 0.71 0.80 0.45 0.53
4 days dry x a 0.72 (n = 8) a 0.88 (n = 8) a 0.93 (n = 8) a 0.80 (n = 8) a 0.57 (n = 32)
SD 0.53 0.63 0.85 0.57 0.48
7 days dry x a 2.20 (n = 8) a 0.92 (n = 8) a 0.55 (n = 8) a 0.81 (n = 8) a 0.71 (n = 32)
SD 3.02 0.67 0.43 0.72 0.64
10 days dry x a 3.93 (n = 8) ab 0.97 (n = 8) a 0.80 (n = 8) ab 0.84 (n = 8) ab 0.95 (n = 32)
SD 5.40 0.53 0.57 0.65 0.66
bLf
0 days dry x c 0.96 (n = 8) c 1.40 (n = 8) c 0.72 (n = 8) c 0.95 (n = 8) c 0.81 (n = 32)
SD 0.54 1.24 0.26 1.03 0.89
2 days dry x c 1.92 (n = 8) c 4.55 (n = 8) c 4.35 (n = 8) c 1.94 (n = 8) c 2.90 (n = 32)
SD 1.02 5.27 6.89 1.19 3.40
4 days dry x c 6.44 (n = 8) c 10.8 (n = 8) c 8.90 (n = 8) c 5.40 (n = 8) c 10.5 (n = 32)
SD 8.80 8.89 3.84 4.43 12.44
7 days dry x c 23.8 (n = 8) cd 14.4 (n = 8) cd 6.50 (n = 8) c 21.2 (n = 8) cd 15.1 (n = 32)
SD 13.35 14.12 3.76 15.68 15.02
10 days dry x e 14.0 (n = 8) e 15.1 (n = 8) e 10.5 (n = 8) e 13.2 (n = 8) e 22.1 (n = 32)
SD 8.96 17.09 8.00 9.85 29.05
DMSCC
(×1000)
0 days dry x e 628 (n = 8) e 380 (n = 8) e 505 (n = 8) e 378 (n = 8) e 264 (n = 32)
SD 607 282 945 341 215
2 days dry x e 1476 (n = 8) e 2274 (n = 8) e 1892 (n = 8) e 1811 (n = 8) e 1280 (n = 32)
SD 1861 2955 2905 1621 1284
4 days dry x e 5171 (n = 8) e 1841 (n = 8) e 4296 (n = 8) e 2929 (n = 8) e 2012 (n = 32)
SD 5589 1269 4887 2542 1709
7 days dry x e 6236 (n = 8) e 3607 (n = 8) e 3449 (n = 8) e 3601 (n = 8) e 3993 (n = 32)
SD 3470 2886 4323 3412 3643
10 days dry x e 7001 (n = 8) e 4167 (n = 8) e 5622 (n = 8) e 3014 (n = 8) e 5407 (n = 32)
SD 1700 2021 2145 2154 3078
a–e Means within a row with different superscripts differ at p < 0.05. BSA = bovine serum albumin; bLf = bovine lactoferrin; DMSCC =
direct microscopic somatic cell count. x = mean; SD = standard deviation.
4. Discussion
This is the first study conducted in North America to investigate the efficacy of using
intramammary casein hydrolysate to supplement or possibly replace standard dry cow
therapy. The results from this study demonstrate an association between the use of casein
hydrolysate and a faster increase in the milk concentration of some markers of mammary
involution in comparison with standard industry dry treatment during the early dry period.
Involuted bovine mammary glands are quite resistant to new IMI [33,35], which suggests
that intramammary use of casein hydrolysate may be beneficial to udder health at the time
of dry-off, with or without the addition of an antibiotic. All markers of involution increased
from the time of dry-off and treatment to the final sampling 10 days later regardless of
treatment, consistent with previously published studies [29,34].
Increases in the concentration of bovine lactoferrin and bovine serum albumin in
milk have been used as indicators of bovine mammary involution previously [29,33,34,36].
Besides being an indicator of mammary involution, bovine lactoferrin plays an immunolog-
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ically important role during mammary involution, by binding available iron and making it
unavailable for iron-dependent bacteria to grow [37,38]. It has been reported that lactoferrin
presents a robust defense against IMI [36–38]. One week after drying off, the concentration
of lactoferrin was higher in cows that were treated with casein hydrolysate compared with
the controls and all but one other treatment. Therefore, it is possible these animals expe-
rienced udder health benefits, both because of faster involution as indicated by a higher
concentration of lactoferrin and possibly because of its immunologic effects as well [37].
This is an interesting and valuable outcome when considering the use of alternatives to
antimicrobial dry treatment.
It was observed that the cure rate during the dry period of IMI that were present
pre-treatment and the rate of new IMI during the dry period were not different between
any of the treatment groups, including casein hydrolysate, antibiotic dry treatment or teat
sealant in combinations. However, the logistics of the project necessitated a relatively small
sample size of 16 cows, which contributed to this lack of statistical significance because
of the small numbers of IMI. This is a preliminary study, and future studies with a larger
sample size are needed.
5. Conclusions
Cows experienced no mammary quarters with proportional milk production loss
following any of the dry treatments containing casein hydrolysate. Restricting blanket use
of dry cow therapy in the U.S. dairy industry may become a reality in the future, and the
results of this study show that intramammary use of casein hydrolysate was associated
with faster increases in some measures of bovine mammary involution during the early
dry period. The use of casein hydrolysate alone or combined with internal teat sealant may
be an alternative to antibiotic dry cow therapy.
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